Profile data is unavailable for this security.
About the company
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
- Revenue in SEK (TTM)1.13bn
- Net income in SEK151.22m
- Incorporated1988
- Employees403.00
- LocationRaySearch Laboratories AB (publ)Eugeniavagen 18CSTOCKHOLM 104 30SwedenSWE
- Phone+46 851053000
- Fax+46 854506139
- Websitehttps://www.raysearchlabs.com/
Mergers & acquisitions
| Acquired company | RAY B:STO since announced | Transaction value |
|---|---|---|
| Pharmacolog i Uppsala AB-Pharmaceutical Asset | 87.12% | 811.00k |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sedana Medical AB (publ) | 168.68m | -41.47m | 2.29bn | 81.00 | -- | 2.36 | -- | 13.57 | -0.4175 | -0.4175 | 1.70 | 9.79 | 0.1609 | 1.19 | 10.82 | 2,135,139.00 | -3.95 | -5.77 | -4.17 | -6.08 | 70.32 | 64.06 | -24.59 | -36.13 | 5.66 | -- | 0.0081 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
| BICO Group AB | 2.25bn | -786.80m | 3.04bn | 828.00 | -- | 1.05 | -- | 1.35 | -11.15 | -15.20 | 31.92 | 41.79 | 0.3602 | 2.15 | 4.47 | 2,547,964.00 | -12.62 | -- | -14.44 | -- | 55.70 | -- | -35.03 | -- | 2.23 | -0.5705 | 0.397 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| Medistim ASA | 519.02m | 100.58m | 3.20bn | 152.00 | 31.76 | 8.65 | 25.63 | 6.16 | 5.70 | 5.70 | 29.41 | 20.93 | 1.17 | 0.7319 | 6.34 | 3,542,250.00 | 22.71 | 22.93 | 27.59 | 28.52 | 79.49 | 78.25 | 19.38 | 20.64 | 2.40 | -- | 0.0262 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| Detection Technology Oyj | -1.14tn | -1.14tn | 3.20bn | 464.00 | -- | 3.82 | -- | -- | -- | -- | -- | 5.03 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.39 | -- | 0.00 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| RaySearch Laboratories AB (publ) | 1.13bn | 151.22m | 4.46bn | 403.00 | 38.02 | 7.48 | 10.63 | 3.95 | 4.41 | 4.41 | 32.91 | 22.41 | 0.5701 | 4.50 | 3.11 | 2,901,244.00 | 7.64 | 1.29 | 11.80 | 1.88 | 90.48 | 90.57 | 13.40 | 2.55 | 1.17 | -- | 0.3937 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| Surgical Science Sweden AB | 838.25m | 197.72m | 6.08bn | 265.00 | 30.74 | 1.32 | 23.80 | 7.25 | 3.87 | 3.87 | 16.43 | 90.02 | 0.1695 | 1.49 | 7.35 | 3,224,027.00 | 4.00 | 4.49 | 4.26 | 4.78 | 68.51 | 70.06 | 23.59 | 23.75 | 3.46 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| CellaVision AB | 726.40m | 145.06m | 6.34bn | 221.00 | 43.74 | 8.58 | 34.02 | 8.73 | 6.08 | 6.08 | 30.45 | 31.00 | 0.783 | 1.76 | 6.66 | 3,185,965.00 | 15.64 | 15.30 | 18.18 | 18.24 | 66.62 | 69.03 | 19.97 | 19.98 | 1.99 | 103.58 | 0.0574 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 29 Sep 2023 | 2.71m | 10.17% |
| Financi�re de l'�chiquier SAas of 27 Mar 2024 | 2.33m | 8.77% |
| Swedbank Robur Fonder ABas of 30 Aug 2024 | 1.80m | 6.76% |
| Invesco Advisers, Inc.as of 29 Sep 2023 | 1.39m | 5.20% |
| Andra AP-fondenas of 31 Dec 2023 | 1.22m | 4.59% |
| Amundi Asset Management SA (Investment Management)as of 31 Jul 2024 | 914.79k | 3.44% |
| Deka Investment GmbHas of 30 Jun 2024 | 911.50k | 3.42% |
| Herald Investment Management Ltd.as of 31 Dec 2023 | 598.97k | 2.25% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 452.09k | 1.70% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 332.34k | 1.25% |
